Credit Suisse Ag Anavex Life Sciences Corp. Transaction History

Credit Suisse Ag

$101 Billion
Q1 2024

A detailed history of Credit Suisse Ag transactions in Anavex Life Sciences Corp. stock. As of the latest transaction made, Credit Suisse Ag holds 98,689 shares of AVXL stock, worth $735,233. This represents 0.0% of its overall portfolio holdings.

Number of Shares

98,689

Previous 97,464 1.26%

Holding current value

$735,233

Previous $907,000 44.65%

% of portfolio

0.0%

Previous 0.0%

25 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 10, 2024	BUY	$4.55 - $6.75 $5,573 - $8,268	1,225 Added 1.26%	98,689 $502,000
Q4 2023 Feb 08, 2024	BUY	$5.04 - $9.95 $1,310 - $2,587	260 Added 0.27%	97,464 $907,000
Q3 2023 Nov 13, 2023	SELL	$6.55 - $9.37 $113,118 - $161,819	-17,270 Reduced 15.09%	97,204 $636,000
Q2 2023 Aug 11, 2023	BUY	$7.66 - $9.5 $193,882 - $240,454	25,311 Added 28.39%	114,474 $930,000
Q1 2023 May 10, 2023	BUY	$8.32 - $11.75 $34,869 - $49,244	4,191 Added 4.93%	89,163 $764,000
Q4 2022 Feb 13, 2023	BUY	$7.65 - $14.43 $139,597 - $263,318	18,248 Added 27.35%	84,972 $786,000
Q3 2022 Nov 10, 2022	BUY	$8.9 - $12.86 $61,552 - $88,939	6,916 Added 11.56%	66,724 $689,000
Q2 2022 Aug 12, 2022	BUY	$7.31 - $12.84 $43,121 - $75,743	5,899 Added 10.94%	59,808 $599,000
Q1 2022 May 16, 2022	BUY	$9.74 - $17.69 $93,533 - $169,877	9,603 Added 21.67%	53,909 $663,000
Q4 2021 Feb 14, 2022	BUY	$16.88 - $23.31 $11,090 - $15,314	657 Added 1.51%	44,306 $769,000
Q3 2021 Nov 12, 2021	BUY	$16.82 - $25.75 $62,553 - $95,764	3,719 Added 9.31%	43,649 $784,000
Q2 2021 Aug 16, 2021	BUY	$10.16 - $28.86 $405,688 - $1.15 Million	39,930 New	39,930 $913,000
Q1 2021 May 14, 2021	SELL	$5.17 - $16.13 $77,917 - $243,095	-15,071 Closed	0 $0
Q4 2020 Feb 12, 2021	BUY	$4.01 - $7.58 $60,434 - $114,238	15,071 New	15,071 $81,000
Q2 2020 Aug 12, 2020	SELL	$2.62 - $5.2 $28,558 - $56,680	-10,900 Closed	0 $0
Q1 2020 May 13, 2020	BUY	$2.38 - $5.81 $25,942 - $63,328	10,900 New	10,900 $35,000
Q2 2019 Aug 14, 2019	SELL	$2.75 - $3.7 $60,230 - $81,037	-21,902 Closed	0 $0
Q1 2019 May 14, 2019	SELL	$1.68 - $3.42 $24,533 - $49,942	-14,603 Reduced 40.0%	21,902 $67,000
Q4 2018 Feb 13, 2019	SELL	$1.25 - $2.75 $2 - $5	-2 Reduced 0.01%	36,505 $57,000
Q3 2018 Nov 13, 2018	SELL	$2.23 - $3.82 $1,893 - $3,243	-849 Reduced 2.27%	36,507 $100,000
Q2 2018 Aug 14, 2018	SELL	$2.08 - $4.26 $27,339 - $55,993	-13,144 Reduced 26.03%	37,356 $98,000
Q1 2018 May 15, 2018	BUY	$2.32 - $3.44 $7,674 - $11,379	3,308 Added 7.01%	50,500 $140,000
Q4 2017 Feb 14, 2018	SELL	$3.12 - $4.94 $46,250 - $73,230	-14,824 Reduced 23.9%	47,192 $153,000
Q3 2017 Nov 14, 2017	BUY	$3.42 - $4.87 $63,276 - $90,104	18,502 Added 42.52%	62,016 $257,000
Q2 2017 Aug 14, 2017	BUY	N/A	43,514	43,514 $231,000

Others Institutions Holding AVXL

# of Institutions

154

Shares Held

27.3M

Call Options Held

515K

Put Options Held

838K

View Full List

About ANAVEX LIFE SCIENCES CORP.

Ticker AVXL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 77,942,800
Market Cap $581M
Description
Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system (CNS) diseases. Its lead drug candidate is ANAVEX 2-73, which is in Phase III clinical trial for the treatment of Alzheimer's disease; Phase III clinical trial to treat pediatric patien...

More about AVXL

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Credit Suisse Ag, based on Form 13F filings with the SEC.

News

Stay updated on Credit Suisse Ag with notifications on news.

Account